Compare Regeneron Pharmaceuticals Inc (REGN) vs Veritone Inc (VERI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Regeneron Pharmaceuticals Inc vs Veritone Inc — how do they compare? Regeneron Pharmaceuticals Inc trades at $652 (market cap $70.79B), while Veritone Inc trades at $1.13 (market cap $105.04M). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 673.9× Veritone Inc's market cap, and Regeneron Pharmaceuticals Inc pays a 0.56% dividend while Veritone Inc pays none. Which is the better fit depends on your goals.
| REGN | VERI | |
|---|---|---|
Market Cap | $70.79B | $105.04M |
Sector | Health | Technology |
52-Week High | $812.27 | $8.39 |
52-Week Low | $545.46 | $1.02 |
Enterprise Value | $64.74B | $137.07M |
Dividend Yield | 0.56% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Regeneron Pharmaceuticals (REGN) trades at $675.19, down 0.22% on the day, with a bullish technical signal from moving averages. The company shows strong fundamentals with a P/E of 16.41, net income margin of 29.65%, and consistent earnings beats in recent quarters. However, sentiment is clouded by a securities class action lawsuit related to a Phase 3 clinical trial failure disclosed in July 2026.
The outlook remains positive based on analyst consensus with a $764.50 price target and 69% buy ratings, but near-term volatility is likely due to legal overhangs. Investment opportunity lies in robust profitability and growth prospects, while key risks include litigation outcomes and clinical trial setbacks.
VERI trades at $1.05, up 2.94% today, but remains in a bearish technical trend with negative earnings and cash flow. The company reported a net loss of $111.73M in 2025, with revenue of $92.19M, and faces multiple securities class action lawsuits. Analyst ratings are split evenly between Buy and Hold, with a minority Sell rating, reflecting uncertainty amid financial challenges and legal overhangs.
The outlook is highly speculative due to persistent losses, negative margins, and legal risks. While the low P/S ratio of 0.87 may attract value hunters, the stock carries significant downside risk from operational cash burn and potential settlement costs. Investors should weigh the speculative potential against substantial financial and litigation headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →About Veritone Inc
Veritone is a leading provider of enterprise AI software and solutions, centered on its proprietary AI operating system, aiWARE™. The platform orchestrates a vast ecosystem of machine learning models to transform unstructured data—such as audio, video, and text—into actionable intelligence. Serving the media, entertainment, and public sectors, Veritone is a critical infrastructure partner for organizations looking to monetize data archives and operationalize AI at scale.
Read more on VERI →
